MX2017007245A - Metodos de tratamiento de la fibrosis. - Google Patents
Metodos de tratamiento de la fibrosis.Info
- Publication number
- MX2017007245A MX2017007245A MX2017007245A MX2017007245A MX2017007245A MX 2017007245 A MX2017007245 A MX 2017007245A MX 2017007245 A MX2017007245 A MX 2017007245A MX 2017007245 A MX2017007245 A MX 2017007245A MX 2017007245 A MX2017007245 A MX 2017007245A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- treating fibrosis
- patient
- inhibitor
- btk inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B31/00—Disazo and polyazo dyes of the type A->B->C, A->B->C->D, or the like, prepared by diazotising and coupling
- C09B31/02—Disazo dyes
- C09B31/12—Disazo dyes from other coupling components "C"
- C09B31/14—Heterocyclic components
- C09B31/143—1,2-Diazoles
- C09B31/147—Pyrazoles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen métodos para el tratamiento de la fibrosis en un paciente, que comprenden administrarle a un paciente que lo necesite una cantidad terapéuticamente eficaz de un inhibidor de ACK (por ejemplo, un inhibidor de BTK, tal como, por ejemplo, un inhibidor de BTK irreversible, tal como, por ejemplo, ibrutinib).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086945P | 2014-12-03 | 2014-12-03 | |
| PCT/US2015/063475 WO2016090021A1 (en) | 2014-12-03 | 2015-12-02 | Methods of treating fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017007245A true MX2017007245A (es) | 2018-02-16 |
Family
ID=56092404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017007245A MX2017007245A (es) | 2014-12-03 | 2015-12-02 | Metodos de tratamiento de la fibrosis. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9844552B2 (es) |
| EP (1) | EP3226864A4 (es) |
| JP (1) | JP2017536397A (es) |
| CN (1) | CN106999482A (es) |
| AR (1) | AR102871A1 (es) |
| AU (1) | AU2015358503A1 (es) |
| BR (1) | BR112017011897A2 (es) |
| CA (1) | CA2968866A1 (es) |
| HK (1) | HK1244692A1 (es) |
| MX (1) | MX2017007245A (es) |
| TW (2) | TW201740953A (es) |
| WO (1) | WO2016090021A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2928721C (en) | 2013-10-25 | 2020-12-22 | Pharmacyclics Llc | Use of ibrutinib for treating and preventing chronic graft versus host disease |
| AR102871A1 (es) * | 2014-12-03 | 2017-03-29 | Pharmacyclics Llc | Métodos de tratamiento de fibrosis |
| CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| CN113694187A (zh) * | 2021-07-20 | 2021-11-26 | 上海市东方医院（同济大学附属东方医院） | 一种用于抑制心肌纤维化的药物组合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006279794B2 (en) * | 2005-08-12 | 2011-04-07 | Synta Pharmaceuticals Corp. | Pyrazole compounds that modulate HSP90 activity |
| PT2526933E (pt) | 2006-09-22 | 2015-06-23 | Pharmacyclics Inc | Inibidores da tirosina-quinase de bruton |
| AU2009270856B2 (en) | 2008-07-16 | 2013-07-25 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors |
| WO2011133609A2 (en) * | 2010-04-19 | 2011-10-27 | The Translational Genomics Research Institute | Methods and kits to predict therapeutic outcome of btk inhibitors |
| KR20140058543A (ko) * | 2011-07-08 | 2014-05-14 | 노파르티스 아게 | 신규 피롤로 피리미딘 유도체 |
| EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| ES2709509T3 (es) | 2013-08-12 | 2019-04-16 | Pharmacyclics Llc | Procedimientos para el tratamiento de cáncer amplificado por HER2 |
| CA2928721C (en) | 2013-10-25 | 2020-12-22 | Pharmacyclics Llc | Use of ibrutinib for treating and preventing chronic graft versus host disease |
| WO2015084857A1 (en) | 2013-12-02 | 2015-06-11 | Pharmacyclics, Inc. | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
| RU2646758C2 (ru) | 2013-12-05 | 2018-03-07 | Ф. Хоффманн-Ля Рош Аг | Гетероарил пиридоны и азапиридоны с электрофильной функциональностью |
| US9982265B2 (en) | 2014-03-28 | 2018-05-29 | Board Of Regents, The University Of Texas System | Inhibition of Bruton's tyrosine kinase (Btk) in the lung to treat severe lung inflammation and lung injury |
| AR102871A1 (es) | 2014-12-03 | 2017-03-29 | Pharmacyclics Llc | Métodos de tratamiento de fibrosis |
-
2015
- 2015-12-01 AR ARP150103925A patent/AR102871A1/es unknown
- 2015-12-02 TW TW106106688A patent/TW201740953A/zh unknown
- 2015-12-02 CN CN201580065663.4A patent/CN106999482A/zh active Pending
- 2015-12-02 JP JP2017529401A patent/JP2017536397A/ja active Pending
- 2015-12-02 BR BR112017011897-1A patent/BR112017011897A2/pt not_active Application Discontinuation
- 2015-12-02 MX MX2017007245A patent/MX2017007245A/es unknown
- 2015-12-02 CA CA2968866A patent/CA2968866A1/en not_active Abandoned
- 2015-12-02 WO PCT/US2015/063475 patent/WO2016090021A1/en active Application Filing
- 2015-12-02 US US14/957,294 patent/US9844552B2/en active Active
- 2015-12-02 EP EP15864946.7A patent/EP3226864A4/en not_active Withdrawn
- 2015-12-02 AU AU2015358503A patent/AU2015358503A1/en not_active Abandoned
- 2015-12-02 TW TW104140382A patent/TW201625257A/zh unknown
-
2017
- 2017-12-08 US US15/836,482 patent/US10226466B2/en active Active
-
2018
- 2018-03-27 HK HK18104208.0A patent/HK1244692A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20160199376A1 (en) | 2016-07-14 |
| BR112017011897A2 (pt) | 2018-07-03 |
| HK1244692A1 (zh) | 2018-08-17 |
| EP3226864A1 (en) | 2017-10-11 |
| TW201625257A (zh) | 2016-07-16 |
| AU2015358503A1 (en) | 2017-06-08 |
| CN106999482A (zh) | 2017-08-01 |
| WO2016090021A1 (en) | 2016-06-09 |
| US10226466B2 (en) | 2019-03-12 |
| US9844552B2 (en) | 2017-12-19 |
| EP3226864A4 (en) | 2018-04-04 |
| AR102871A1 (es) | 2017-03-29 |
| US20180153896A1 (en) | 2018-06-07 |
| CA2968866A1 (en) | 2016-06-09 |
| JP2017536397A (ja) | 2017-12-07 |
| TW201740953A (zh) | 2017-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202208792B (en) | Methods of treating and preventing graft versus host disease | |
| PH12015502075B1 (en) | Treatment of cataplexy | |
| NZ730809A (en) | Methods for treating filoviridae virus infections | |
| MX2017004471A (es) | Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística. | |
| PH12016501830A1 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
| PH12016501790B1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
| EP4282479A3 (en) | Use of pridopidine to treat depression or anxiety | |
| GB2541571A (en) | Pharmaceutical compositions | |
| NZ760790A (en) | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof | |
| PH12016501788A1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
| PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| EA201692534A1 (ru) | Способы лечения гипотонии | |
| MX2017007245A (es) | Metodos de tratamiento de la fibrosis. | |
| IN2014MU00916A (es) | ||
| PH12014502065A1 (en) | Vesicular formulations | |
| MX2016012758A (es) | Composicion hiperosmolar de acido hialuronico. | |
| EA201690446A1 (ru) | Лечение множественной миеломы | |
| MX2018011379A (es) | Tratamiento del prurito uremico. | |
| MX2016002307A (es) | Tratamiento para el cancer. | |
| PH12014000104A1 (en) | Therapeutic methods and compositions for treating diabetes | |
| WO2015187733A3 (en) | Myostatin inhibitors for treatment of diabetes | |
| IN2014DE00822A (es) |